Radius Health, Inc.: directors' dealings · United States · SEC (Form 4)

About Radius Health, Inc.

Radius Health, Inc. (ticker: RDUS) is a U.S.-listed biopharmaceutical company quoted on the NASDAQ market in the United States. The company has historically focused on bone health and, more broadly, adjacent therapeutic areas with unmet medical need. Its core commercial story has revolved around TYMLOS® (abaloparatide), an injectable osteoporosis treatment launched in the U.S. in 2017 for postmenopausal women at high risk of fracture. Radius later broadened its bone-health platform through additional commercial assets, including BINOSTO®, helping the company deepen its presence in osteoporosis care. ([radiuspharm.com](https://radiuspharm.com/?utm_source=openai)) Radius was founded in Boston, Massachusetts, and has been operated as a specialty biopharmaceutical business with a commercial rather than a pure research profile. Its model has centered on specialist engagement, market access, and targeted promotion to physicians treating osteoporosis. From a competitive standpoint, the company has not competed as a broad-based pharma giant; instead, its position has been defined by a focused franchise strategy in a niche market where clinical differentiation, intellectual property, and commercial execution matter disproportionately. That niche orientation has made RDUS relevant to investors looking for a concentrated specialty-pharma exposure rather than a diversified large-cap healthcare platform. ([radiuspharm.com](https://radiuspharm.com/?utm_source=openai)) In terms of strategic development, Radius also pursued partnerships to expand the reach of its lead asset. In January 2025, the company announced a licensing agreement with Pharmanovia to register and commercialize abaloparatide in China and selected Asia-Pacific territories, a move that suggests management has sought to extend value beyond the U.S. without bearing the full burden of building a local infrastructure. More recently, in March 2026, Paratek Pharmaceuticals completed its combination with Radius Health, indicating that the business entered a new consolidation phase and that Radius’ assets and commercial footprint became part of a broader specialty-medicine platform. For investors, that is a key recent development because it can alter the company’s standalone profile, governance structure, and future earnings visibility. ([radiuspharm.com](https://radiuspharm.com/radius-pharmaceuticals-announces-licensing-agreement-with-pharmanovia-to-register-and-commercialize-abaloparatide-in-china-and-select-asia-pacific-territories/?utm_source=openai)) Overall, Radius Health has been best understood as a specialty biopharmaceutical company built around a small number of high-value assets, most notably TYMLOS®. Its investment case has depended on sustained commercial performance, protection of franchise economics, and portfolio actions such as licensing and combination transactions. For French, Belgian, and Swiss investors following U.S. healthcare names, RDUS is therefore a case study in focused specialty pharma: scientifically targeted, commercially concentrated, and increasingly shaped by M&A rather than by a broad internal pipeline. ([radiuspharm.com](https://radiuspharm.com/?utm_source=openai))